METHODS: In a 36-week, multicenter, double-blind study, 313 participants with idiopathic OAB and urinary urgency incontinence inadequately managed with anticholinergics were randomized to placebo or one of five onabotulinumtoxinA doses. Assessment included a modified OAB-Patient Satisfaction with Treatment Questionnaire (PSTQ) and four Patient Global Assessment questions assessed changes in symptoms, quality of life, activity limitations, and emotions.
RESULTS: Mean changes from baseline in OAB-PSTQ scores for the main module (Q2-Q13) at week 12 were greater for each onabotulinumtoxinA group (range, -31.5% to -48.9%) versus placebo (-17.6%). Greater proportions of patients in onabotulinumtoxinA groups attained their primary goal (range, 34.5% to 65.3%) versus placebo (23.7%).
CONCLUSIONS: Patients with OAB are more likely to be satisfied and/or achieve their primary treatment goal with onabotulinumtoxinA treatment than with placebo, consistent with symptom improvements.
Written by:
Brubaker L, Gousse A, Sand P, Thompson C, Patel V, Zhou J, Jenkins B, Sievert KD. Are you the author?
Department of Obstetrics and Gynecology, Stritch School of Medicine, Loyola University Chicago, 2160 S. First Avenue, Chicago, IL, 60153, USA.
Reference: Int Urogynecol J. 2012 Jan 25. Epub ahead of print.
doi: 10.1007/s00192-011-1655-1
PubMed Abstract
PMID: 22273813
UroToday.com Overactive Bladder (OAB) Section
